On : 24 September 2024
• The global Durvalumab market size was valued at US$ 2.34 billion in 2024 and is projected to reach US$ 4.56 billion by 2030, at a CAGR of 11.8% during the forecast period 2024-2030.
• United States Durvalumab market size was valued at US$ 765 million in 2024 and is projected to reach US$ 1.43 billion by 2030, at a CAGR of 11.0% during the forecast period 2024-2030.
• Durvalumab Market provides a deep insight into the global Durvalumab market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
• The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market, NonPeptide Drugs of Angiotensin II Receptor Antagonist Market introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
2.4mL Injection
10mL Injection
• Locally Advanced Urothelial Carcinoma
• Metastatic Urothelial Carcinoma
• Other
